Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lixudebart - Alentis Therapeutics

Next Previous
Drug Profile

Lixudebart - Alentis Therapeutics

Alternative Names: ALE-F02; ALE.F02

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM; The Mount Sinai Hospital; University of Strasbourg
  • Developer Alentis Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action Claudin 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glomerulonephritis
  • Phase I Hepatic fibrosis
  • Preclinical Idiopathic pulmonary fibrosis
  • No development reported Renal fibrosis

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for phase-I development in Hepatic-fibrosis(In volunteers) in Switzerland (Parenteral)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Renal-fibrosis(In volunteers) in Switzerland (Parenteral)
  • 09 Jan 2025 Adverse events data from a phase Ib FEGATO-01 trial in Hepatic fibrosis released by Alentis Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top